What is Syfovre™?
Syfovre™ is a prescription eye injection, used to treat geographic atrophy (GA), the dry advanced form of age-related macular degeneration (AMD). Syfovre™ helps regulate an overactivated part of the immune system in your eye. This overactivation can contribute to the progression of GA. It is important to know that GA cannot be cured, and any vision loss as a result of lesion growth cannot be reversed.
How do I know if I qualify for a Syfovre™ treatment?
You must have a comprehensive dilated eye exam with one of our retina specialists to see if you qualify for a Syfovre™ injection. The retina specialist must closely examine the back of the eye to determine if geographic atrophy is present. They may also order diagnostic imaging tests at the time of your visit.
Complications/side effects of some treatments for geographic atrophy
Syfovre™ injections are very new. Manufacturer literature suggests that these side effects are possible:
- Eye pain
- Subconjunctival hemorrhage, or bleeding in your conjunctiva (white part of your eye)
- Floaters in your vitreous humor ( clear gel that fills the eyeball)
- Neovascularization of the eye (wet AMD)
What should I expect if I receive a Syfovre™ injection?
Syfovre™ was studied in two phase 3 clinical trials of over 1200 people with GA. In both trials, lesion growth slowed down for patients who received Syfovre™ versus those who did not receive Syfovre™. It is important to understand that Syfovre™ will not improve your vision, or bring back vision that is already gone. The goal of the Syfovre™ injection is to slow the progression of the geographic atrophy lesions that cause vision loss.
Are there any other treatments beside Syfovre™ for geographic atrophy?
Currently, Syfovre™ is the only FDA approved treatment for GA. There are other similar treatments under investigation in clinical trials that are expected to be approved by the FDA in the near future.